Stay updated on Reslizumab in EGPA: Clinical Trial

Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Reslizumab in EGPA: Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s footer shows an updated site revision identifier, with no apparent changes to the study record.
    Difference
    0.1%
    Check dated 2026-11-18T02:13:53.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The study page displays details for the reslizumab EGPA trial, including its treatment plan, eligibility criteria, outcomes, and contact information. It also shows the study’s recruiting status and record history.
    Difference
    45%
    Check dated 2026-11-11T01:29:35.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer’s revision label changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T23:38:59.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    A general NIH banner was added about the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision number changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:29:54.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-07T00:38:07.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, blocking access to the record and replacing the previous study details with a standard error page.
    Difference
    17%
    Check dated 2026-09-23T00:42:17.000Z thumbnail image

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.